Skip to main content
Vivoryon Therapeutics N.V. logo

Vivoryon Therapeutics N.V. — Investor Relations & Filings

Ticker · VVY ISIN · NL00150002Q7 LEI · 3912004AMB0KGZXZYJ15 AS Manufacturing
Open in API
Filings indexed 400 across all filing types
Latest filing 2024-05-23 Earnings Release
Country NL Netherlands
Listing AS VVY

About Vivoryon Therapeutics N.V.

https://www.vivoryon.com/

Vivoryon Therapeutics N.V. is a clinical-stage precision medicine company focused on developing first-in-class therapies by targeting post-translational modifications of proteins. The company's scientific approach centers on inhibiting glutaminyl cyclases (QPCT and QPCTL), enzymes that catalyze pyroglutamate formation, a process implicated in the progression of various diseases. Its lead product candidate, varoglutamstat, is an orally administered small molecule QPCT/L inhibitor. Vivoryon is advancing its therapeutic pipeline for patients with inflammatory, fibrotic, and neurodegenerative diseases, with a strategic focus on conditions such as chronic kidney disease.

Recent filings

Filing Released Lang Actions
Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
Earnings Release Classification · 98% confidence The document explicitly states it announces 'financial results for the first quarter of 2024' and provides a 'corporate update.' It details revenues, R&D expenses, net loss for the period ending March 31, 2024, and provides a financial outlook. This content structure is characteristic of a periodic financial results announcement, specifically for a quarter, which aligns with the 'Earnings Release' (ER) definition. Although it contains detailed data tables, the primary purpose is the release of period results, not a comprehensive annual filing (10-K) or a standalone audit report (AR). It is not merely an announcement of a report's publication (RPA) because it contains the actual results summary, not just a link to an attached document. The mention of a conference call following the presentation further supports the ER classification. Q1 2024
2024-05-23 English
Vivoryon Therapeutics N.V. to Hold its 2024 Annual General Meeting on June 21, 2024
AGM Information Classification · 98% confidence The document explicitly announces that the '2024 Annual General Meeting will be held on Friday, June 21, 2024'. This directly relates to the scheduling and announcement of the AGM. According to the definitions, 'AGM Information (Code: AGM-R)' covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. Although this is an announcement of the meeting date, it serves as the primary notification for the AGM event itself, making AGM-R the most appropriate classification over a general RPA or RNS, as the subject matter is highly specific to the AGM.
2024-05-08 English
Annual Report 2023
Annual Report Classification · 100% confidence The document is titled 'Vivoryon Therapeutics N.V. Annual Report 2023' and contains comprehensive sections including the Report by the Executive Management Board, Financial Statements (Statements of Operations, Financial Position, Cash Flows), and Notes to the Financial Statements. It covers the fiscal year ended December 31, 2023. It is a full annual report, not an announcement or a summary, and meets the criteria for a 10-K equivalent. FY 2023
2024-04-24 English
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
Earnings Release Classification · 100% confidence The document explicitly states in the title and opening paragraph that it reports 'Full Year 2023 Financial Results' and provides financial guidance for the 'twelve-month period ended December 31, 2023'. This content structure, covering comprehensive annual performance, R&D updates, strategic shifts, and detailed financial statements (Revenues, R&D expenses, Net loss, Cash position), is characteristic of a full annual report filing. Although it is presented as a press release announcing the results, the depth and scope of the financial data provided strongly suggest it is the primary document summarizing the annual performance, which aligns best with the Annual Report (10-K) category, rather than just an Earnings Release (ER) or a Report Publication Announcement (RPA). Given the context of financial reporting, '10-K' is the most appropriate classification for comprehensive annual financial results. FY 2023
2024-04-24 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UNAUDITED INTERIM REPORT AS OF AND FOR THE SIX-MONTH PERIOD ENDED JUNE 30, 2023' for Vivoryon Therapeutics N.V. It contains comprehensive financial statements, including the Statement of Operations, Statement of Financial Position, Statement of Changes in Shareholders' Equity, and Statement of Cash Flows, along with detailed notes. This meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data for a period shorter than a full fiscal year. H1 2023
2024-04-18 English
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
Report Publication Announcement Classification · 98% confidence The document is a press release dated April 16, 2024, announcing that Vivoryon Therapeutics N.V. will report its 'Full Year 2023 Financial Results and Operational Progress' on April 24, 2024. It explicitly states that the report will be available for download on the Company's website and provides details for a conference call. This structure—announcing the future release of a report (like an Annual Report or Interim Report) along with call details—fits the definition of a Report Publication Announcement (RPA). Although the content relates to the Full Year 2023 results (which would typically be in a 10-K), the document itself is the *announcement* of that future release, not the comprehensive report itself. Given the document length is moderate (5060 chars) and its primary function is to schedule the release and call, RPA is the most appropriate classification based on Rule 2.
2024-04-16 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.